Novel genome-editing tools to model and correct primary immunodeficiencies

Frontiers in Immunology

Volumn 6, Issue MAY, 2015, Pages

  Ott De Bruin, Lisa M ^a,b   Volpi, Stefano ^c,d   Musunuru, Kiran ^e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF GENOA   (Italy)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e Harvard University   (United States)

Author keywords

Cas9; CRISPR Cas9; Endonuclease; Nuclease; PID; SCID; TALEN; ZFN

Indexed keywords

CRISPR ASSOCIATED PROTEIN; ELONGATION FACTOR 1ALPHA; HLA ANTIGEN; INTERLEUKIN 2 RECEPTOR GAMMA; KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; OCTAMER TRANSCRIPTION FACTOR 4; RESTRICTION ENDONUCLEASE; RETROVIRUS VECTOR; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; TRANSCRIPTION FACTOR SOX2; ZINC FINGER NUCLEASE;

CELL DIFFERENTIATION; CRISPR CAS SYSTEM; DNA END JOINING REPAIR; DNA HYBRIDIZATION; DNA MODIFICATION; DOUBLE STRANDED DNA BREAK; EMBRYONIC STEM CELL; EXPERIMENTAL ANIMAL; GENE MUTATION; GENETIC ENGINEERING; GENOME EDITING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNE DEFICIENCY; INJECTION; MISMATCH REPAIR; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; VIRAL GENE THERAPY; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ZYGOTE;

EID: 84934293432     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00250     Document Type: Review

References (132)

1. Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol (2012) 129(3):607-16. doi:10.1016/j.jaci.2012.01.032
2. Borte S, von Dobeln U, Hammarstrom L. Guidelines for newborn screening of primary immunodeficiency diseases. Curr Opin Hematol (2013) 20(1):48-54. doi:10.1097/MOH.0b013e32835a9130
3. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA (2014) 312(7):729-38. doi:10.1001/jama.2014.9132
4. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol (2014) 5:162. doi:10.3389/fimmu.2014.00162
5. Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res (2011) 49(1-3):25-43. doi:10.1007/s12026-010-8191-9
6. Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med (2014) 371(5):434-46. doi:10.1056/NEJMoa1401177
7. Schuetz C, Neven B, Dvorak CC, Leroy S, Ege MJ, Pannicke U, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood (2014) 123(2):281-9. doi:10.1182/blood-2013-01-476432
8. Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol (2010) 126(3):e1-11. doi:10.1016/j.jaci.2010.06.015
9. Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet (2003) 361(9357):553-60. doi:10.1016/S0140-6736(03)12513-5
10. Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med (1999) 340(7):508-16. doi:10.1056/NEJM199902183400703
11. Horn B, Cowan MJ. Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects. J Allergy Clin Immunol (2013) 131(5):1306-11. doi:10.1016/j.jaci.2013.03.014
12. Dvorak CC, Hassan A, Slatter MA, Honig M, Lankester AC, Buckley RH, et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol (2014) 134(4):935.e-43.e. doi:10.1016/j.jaci.2014.06.021
13. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 288(5466):669-72. doi:10.1126/science.288.5466.669
14. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2010) 363(4):355-64. doi:10.1056/NEJMoa1000164
15. Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Adams S, Howe SJ, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med (2011) 3(97):97ra79. doi:10.1126/scitranslmed.3002715
16. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science (1995) 270(5235):475-80. doi:10.1126/science.270.5235.475
17. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 360(5):447-58. doi:10.1056/NEJMoa0805817
18. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 296(5577):2410-3. doi:10.1126/science.1070104
19. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med (1995) 1(10):1017-23. doi:10.1038/nm1095-1017
20. Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Zhang F, Adams S, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med (2011) 3(97):97ra80. doi:10.1126/scitranslmed.3002716
21. Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs HD, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood (2011) 118(6):1675-84. doi:10.1182/blood-2010-11-319376
22. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Diez IA, Dewey RA, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med (2010) 363(20):1918-27. doi:10.1056/NEJMoa1003548
23. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 118(9):3132-42. doi:10.1172/JCI35700
24. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302(5644):415-9. doi:10.1126/science.1088547
25. Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et al. Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity. Sci Transl Med (2014) 6(227):227ra33. doi:10.1126/scitranslmed.3007280
26. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 118(9):3143-50. doi:10.1172/JCI35798
27. Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 371(15):1407-17. doi:10.1056/NEJMoa1404588
28. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science (2003) 300(5626):1749-51. doi:10.1126/science.1083413
29. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol (2004) 2(8):E234. doi:10.1371/journal.pbio.0020234
30. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 24(6):687-96. doi:10.1038/nbt1216
31. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 119(4):964-75. doi:10.1172/JCI37630
32. Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M, et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood (2011) 117(20):5332-9. doi:10.1182/blood-2010-09-306761
33. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet (2011) 12(5):301-15. doi:10.1038/nrg2985
34. Touzot F, Hacein-Bey-Abina S, Fischer A, Cavazzana M. Gene therapy for inherited immunodeficiency. Expert Opin Biol Ther (2014) 14(6):789-98. doi:10.1517/14712598.2014.895811
35. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 341(6148):1233151. doi:10.1126/science.1233151
36. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol (2011) 29(8):731-4. doi:10.1038/nbt.1927
37. Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol (2009) 27(9):851-7. doi:10.1038/nbt.1562
38. Merling RK, Sweeney CL, Chu J, Bodansky A, Choi U, Priel DL, et al. An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease. Mol Ther (2014) 23(1):147-57. doi:10.1038/mt.2014.195
39. Zou J, Sweeney CL, Chou BK, Choi U, Pan J, Wang H, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood (2011) 117(21):5561-72. doi:10.1182/blood-2010-12-328161
40. van Til NP, Sarwari R, Visser TP, Hauer J, Lagresle-Peyrou C, van der Velden G, et al. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. J Allergy Clin Immunol (2014) 133:1116-23. doi:10.1016/j.jaci.2013.10.009
41. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 28(8):839-47. doi:10.1038/nbt.1663
42. Maeder ML, Thibodeau-Beganny S, Sander JD, Voytas DF, Joung JK. Oligomerized pool engineering (OPEN): an 'open-source' protocol for making customized zinc-finger arrays. Nat Protoc (2009) 4(10):1471-501. doi:10.1038/nprot.2009.98
43. Sander JD, Dahlborg EJ, Goodwin MJ, Cade L, Zhang F, Cifuentes D, et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods (2011) 8(1):67-9. doi:10.1038/nmeth.1542
44. Gupta A, Christensen RG, Rayla AL, Lakshmanan A, Stormo GD, Wolfe SA. An optimized two-finger archive for ZFN-mediated gene targeting. Nat Methods (2012) 9(6):588-90. doi:10.1038/nmeth.1994
45. Bhakta MS, Henry IM, Ousterout DG, Das KT, Lockwood SH, Meckler JF, et al. Highly active zinc-finger nucleases by extended modular assembly. Genome Res (2013) 23(3):530-8. doi:10.1101/gr.143693.112
46. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 11(9):636-46. doi:10.1038/nrg2842
47. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, Eichtinger M, et al. Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell (2008) 31(2):294-301. doi:10.1016/j.molcel.2008.06.016
48. Gaj T, Guo J, Kato Y, Sirk SJ, Barbas CF III. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods (2012) 9(8):805-7. doi:10.1038/nmeth.2030
49. Gabriel R, Lombardo A, Arens A, Miller JC, Genovese P, Kaeppel C, et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol (2011) 29(9):816-23. doi:10.1038/nbt.1948
50. Pattanayak V, Ramirez CL, Joung JK, Liu DR. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods (2011) 8(9):765-70. doi:10.1038/nmeth.1670
51. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 25(11):1298-306. doi:10.1038/nbt1353
52. Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, Xia DF, et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods (2011) 8(1):74-9. doi:10.1038/nmeth.1539
53. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol (2007) 25(7):778-85. doi:10.1038/nbt1319
54. Szczepek M, Brondani V, Buchel J, Serrano L, Segal DJ, Cathomen T. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat Biotechnol (2007) 25(7):786-93. doi:10.1038/nbt1317
55. Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science (2011) 333(6051):1843-6. doi:10.1126/science.1204094
56. Holkers M, Maggio I, Liu J, Janssen JM, Miselli F, Mussolino C, et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res (2013) 41(5):e63. doi:10.1093/nar/gks1446
57. Smith C, Gore A, Yan W, Abalde-Atristain L, Li Z, He C, et al. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell (2014) 15(1):12-3. doi:10.1016/j.stem.2014.06.011
58. Suzuki K, Yu C, Qu J, Li M, Yao X, Yuan T, et al. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell (2014) 15(1):31-6. doi:10.1016/j.stem.2014.06.016
59. Mussolino C, Morbitzer R, Lutge F, Dannemann N, Lahaye T, Cathomen T. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res (2011) 39(21):9283-93. doi:10.1093/nar/gkr597
60. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 337(6096):816-21. doi:10.1126/science.1225829
61. Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol (2013) 31(3):230-2. doi:10.1038/nbt.2507
62. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science (2013) 339(6121):823-6. doi:10.1126/science.1232033
63. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 339(6121):819-23. doi:10.1126/science.1231143
64. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. eLife (2013) 2:e00471.
65. Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A (2013) 110(39):15644-9. doi:10.1073/pnas.1313587110
66. Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods (2013) 10(11):1116-21. doi:10.1038/nmeth.2681
67. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol (2013) 31(9):822-6. doi:10.1038/nbt.2623
68. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 157(6):1262-78. doi:10.1016/j.cell.2014.05.010
69. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol (2013) 31(9):839-43. doi:10.1038/nbt.2673
70. Cradick TJ, Fine EJ, Antico CJ, Bao G. CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res (2013) 41(20):9584-92. doi:10.1093/nar/gkt714
71. Kuscu C, Arslan S, Singh R, Thorpe J, Adli M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol (2014) 32(7):677-83. doi:10.1038/nbt.2916
72. Wu X, Scott DA, Kriz AJ, Chiu AC, Hsu PD, Dadon DB, et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol (2014) 32(7):670-6. doi:10.1038/nbt.2889
73. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2014) 33(2):187-97. doi:10.1038/nbt.3117
74. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol (2014) 32(3):279-84. doi:10.1038/nbt.2808
75. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol (2013) 31(9):833-8. doi:10.1038/nbt.2675
76. Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res (2014) 24(1):132-41. doi:10.1101/gr.162339.113
77. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell (2013) 154(6):1380-9. doi:10.1016/j.cell.2013.08.021
78. Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol (2014) 32(6):569-76. doi:10.1038/nbt.2908
79. Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol (2014) 32(6):577-82. doi:10.1038/nbt.2909
80. Zou J, Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S, Chou BK, et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell (2009) 5(1):97-110. doi:10.1016/j.stem.2009.05.023
81. Yusa K, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods (2009) 6(5):363-9. doi:10.1038/nmeth.1323
82. Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT, et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells (2011) 29(11):1717-26. doi:10.1002/stem.718
83. Reinhardt P, Schmid B, Burbulla LF, Schondorf DC, Wagner L, Glatza M, et al. Genetic correction of a LRRK2 mutation in human iPSCs links Parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell (2013) 12(3):354-67. doi:10.1016/j.stem.2013.01.008
84. Genovese P, Schiroli G, Escobar G, Di Tomaso T, Firrito C, Calabria A, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature (2014) 510(7504):235-40. doi:10.1038/nature13420
85. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell (2013) 13(6):653-8. doi:10.1016/j.stem.2013.11.002
86. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 435(7042):646-51. doi:10.1038/nature03556
87. Matsubara Y, Chiba T, Kashimada K, Morio T, Takada S, Mizutani S, et al. Transcription activator-like effector nuclease-mediated transduction of exogenous gene into IL2RG locus. Sci Rep (2014) 4:5043. doi:10.1038/srep05043
88. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 318(5858):1917-20. doi:10.1126/science.1151526
89. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 131(5):861-72. doi:10.1016/j.cell.2007.11.019
90. Warlich E, Kuehle J, Cantz T, Brugman MH, Maetzig T, Galla M, et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther (2011) 19(4):782-9. doi:10.1038/mt.2010.314
91. Zou J, Mali P, Huang X, Dowey SN, Cheng L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood (2011) 118(17):4599-608. doi:10.1182/blood-2011-02-335554
92. Sun N, Zhao H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng (2014) 111(5):1048-53. doi:10.1002/bit.25018
93. Pessach IM, Ordovas-Montanes J, Zhang SY, Casanova JL, Giliani S, Gennery AR, et al. Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol (2011) 127(6):1400.e-7.e. doi:10.1016/j.jaci.2010.11.008
94. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, et al. Disease-specific induced pluripotent stem cells. Cell (2008) 134(5):877-86. doi:10.1016/j.cell.2008.07.041
95. Kennedy M, Awong G, Sturgeon CM, Ditadi A, LaMotte-Mohs R, Zuniga-Pflucker JC, et al. T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures. Cell Rep (2012) 2(6):1722-35. doi:10.1016/j.celrep.2012.11.003
96. Chang CW, Lai YS, Lamb LS Jr, Townes TM. Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cells. PLoS One (2014) 9(5):e97335. doi:10.1371/journal.pone.0097335
97. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 31(10):928-33. doi:10.1038/nbt.2678
98. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science (2014) 343(6166):80-4. doi:10.1126/science.1246981
99. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (2014) 343(6166):84-7. doi:10.1126/science.1247005
100. Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera Mdel C, Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol (2014) 32(3):267-73. doi:10.1038/nbt.2800
101. Zhou Y, Zhu S, Cai C, Yuan P, Li C, Huang Y, et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature (2014) 509(7501):487-91. doi:10.1038/nature13166
102. Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med (2014) 211(11):2137-49. doi:10.1084/jem.20140520
103. Waaijers S, Boxem M. Engineering the Caenorhabditis elegans genome with CRISPR/Cas9. Methods (2014) 68(3):381-8. doi:10.1016/j.ymeth.2014.03.024
104. Sugi T, Sakuma T, Ohtani Y, Yamamoto T. Versatile strategy for isolating transcription activator-like effector nuclease-mediated knockout mutants in Caenorhabditis elegans. Dev Growth Differ (2014) 56(1):78-85. doi:10.1111/dgd.12108
105. Friedland AE, Tzur YB, Esvelt KM, Colaiacovo MP, Church GM, Calarco JA. Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Methods (2013) 10(8):741-3. doi:10.1038/nmeth.2532
106. Huang P, Xiao A, Zhou M, Zhu Z, Lin S, Zhang B. Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol (2011) 29(8):699-700. doi:10.1038/nbt.1939
107. Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol (2008) 26(6):695-701. doi:10.1038/nbt1398
108. Auer TO, Duroure K, Concordet JP, Del Bene F. CRISPR/Cas9-mediated conversion of eGFP-into Gal4-transgenic lines in zebrafish. Nat Protoc (2014) 9(12):2823-40. doi:10.1038/nprot.2014.187
109. Gjini E, Mansour MR, Sander JD, Moritz N, Nguyen AT, Kesarsing M, et al. A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing. Mol Cell Biol (2014) 35(5):789-804. doi:10.1128/MCB.00971-14
110. Meyer M, de Angelis MH, Wurst W, Kuhn R. Gene targeting by homologous recombination in mouse zygotes mediated by zinc-finger nucleases. Proc Natl Acad Sci U S A (2010) 107(34):15022-6. doi:10.1073/pnas.1009424107
111. Carbery ID, Ji D, Harrington A, Brown V, Weinstein EJ, Liaw L, et al. Targeted genome modification in mice using zinc-finger nucleases. Genetics (2010) 186(2):451-9. doi:10.1534/genetics.110.117002
112. Cui X, Ji D, Fisher DA, Wu Y, Briner DM, Weinstein EJ. Targeted integration in rat and mouse embryos with zinc-finger nucleases. Nat Biotechnol (2011) 29(1):64-7. doi:10.1038/nbt.1731
113. Sung YH, Baek IJ, Kim DH, Jeon J, Lee J, Lee K, et al. Knockout mice created by TALEN-mediated gene targeting. Nat Biotechnol (2013) 31(1):23-4. doi:10.1038/nbt.2477
114. Wefers B, Meyer M, Ortiz O, Hrabe de Angelis M, Hansen J, Wurst W, et al. Direct production of mouse disease models by embryo microinjection of TALENs and oligodeoxynucleotides. Proc Natl Acad Sci U S A (2013) 110(10):3782-7. doi:10.1073/pnas.1218721110
115. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell (2013) 153(4):910-8. doi:10.1016/j.cell.2013.04.025
116. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell (2013) 154(6):1370-9. doi:10.1016/j.cell.2013.08.022
117. Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res (2013) 23(5):720-3. doi:10.1038/cr.2013.46
118. Yang H, Wang H, Jaenisch R. Generating genetically modified mice using CRISPR/Cas-mediated genome engineering. Nat Protoc (2014) 9(8):1956-68. doi:10.1038/nprot.2014.134
119. Li F, Cowley DO, Banner D, Holle E, Zhang L, Su L. Efficient genetic manipulation of the NOD-Rag1-/-IL2RgammaC-null mouse by combining in vitro fertilization and CRISPR/Cas9 technology. Sci Rep (2014) 4:5290. doi:10.1038/srep05290
120. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science (2009) 325(5939):433. doi:10.1126/science.1172447
121. Tesson L, Usal C, Menoret S, Leung E, Niles BJ, Remy S, et al. Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol (2011) 29(8):695-6. doi:10.1038/nbt.1940
122. Mashimo T, Takizawa A, Voigt B, Yoshimi K, Hiai H, Kuramoto T, et al. Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases. PLoS One (2010) 5(1):e8870. doi:10.1371/journal.pone.0008870
123. Li W, Teng F, Li T, Zhou Q. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol (2013) 31(8):684-6. doi:10.1038/nbt.2652
124. Yan Q, Zhang Q, Yang H, Zou Q, Tang C, Fan N, et al. Generation of multi-gene knockout rabbits using the Cas9/gRNA system. Cell Regen (Lond) (2014) 3(1):12. doi:10.1186/2045-9769-3-12
125. Wang Y, Fan N, Song J, Zhong J, Guo X, Tian W, et al. Generation of knockout rabbits using transcription activator-like effector nucleases. Cell Regen (Lond) (2014) 3(1):3. doi:10.1186/2045-9769-3-3
126. Flisikowska T, Thorey IS, Offner S, Ros F, Lifke V, Zeitler B, et al. Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. PLoS One (2011) 6(6):e21045. doi:10.1371/journal.pone.0021045
127. Song J, Zhong J, Guo X, Chen Y, Zou Q, Huang J, et al. Generation of RAG 1-and 2-deficient rabbits by embryo microinjection of TALENs. Cell Res (2013) 23(8):1059-62. doi:10.1038/cr.2013.85
128. Fan Z, Li W, Lee SR, Meng Q, Shi B, Bunch TD, et al. Efficient gene targeting in golden Syrian hamsters by the CRISPR/Cas9 system. PLoS One (2014) 9(10):e109755. doi:10.1371/journal.pone.0109755
129. Kurome M, Dahlhoff M, Bultmann S, Krebs S, Blum H, Kessler B, et al. 361 growth hormone receptor mutant pigs produced by using the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated systems in in vitro-produced zygotes. Reprod Fertil Dev (2014) 27(1):269. doi:10.1071/RDv27n1Ab361
130. Zhou X, Xin J, Fan N, Zou Q, Huang J, Ouyang Z, et al. Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer. Cell Mol Life Sci (2014) 72(6):1175-84. doi:10.1007/s00018-014-1744-7
131. Hai T, Teng F, Guo R, Li W, Zhou Q. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. Cell Res (2014) 24(3):372-5. doi:10.1038/cr.2014.11
132. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell (2014) 156(4):836-43. doi:10.1016/j.cell.2014.01.027